Investment bank: Bavarian Nordic's RSV data reduces risk associated with important asset
Wednesday’s positive RSV vaccine candidate results from Bavarian Nordic could pave the way for positive dialog with possible partners before a phase III trial study begins, reads a comment from US-based investment bank Jefferies.
BY RITZAU FINANS, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN
Bavarian Nordic recently publicized positive results from a data study of its RSV vaccine candidate, MVA-BN RSV, which has shown a very good efficacy rate in its phase II study compared to the placebo.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
